Cybin's Deuterated DMTs Show Positive Phase 1 Data, GAD Study Q1 2024
Ticker: HELP · Form: 6-K · Filed: Jan 8, 2024 · CIK: 1833141
| Field | Detail |
|---|---|
| Company | Cybin INC. (HELP) |
| Form Type | 6-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: drug-trial, biotech, clinical-data, patent
TL;DR
**Cybin's psychedelic drugs CYB004 and SPL028 just crushed Phase 1, moving to Phase 2 for anxiety in Q1 2024!**
AI Summary
Cybin Inc. announced positive topline data on January 8, 2024, from its Phase 1 studies for proprietary deuterated DMT molecules, CYB004 and SPL028. The intravenous (IV) CYB004 showed rapid-onset psychedelic effects at lower doses than native DMT, while intramuscular (IM) SPL028 also produced robust, short-duration effects. Both molecules were safe and well-tolerated, leading Cybin to plan for a Phase 2 study in Generalized Anxiety Disorder (GAD) in Q1 2024, which could significantly advance their psychedelic-based treatments and potentially increase the stock's value.
Why It Matters
This positive Phase 1 data for CYB004 and SPL028 suggests Cybin's psychedelic drug candidates are safe and effective, paving the way for a Phase 2 study in Generalized Anxiety Disorder (GAD) and potentially bringing them closer to market.
Risk Assessment
Risk Level: medium — While Phase 1 results are positive, drug development is inherently risky, and future studies (Phase 2, Phase 3) could still fail or face regulatory hurdles.
Analyst Insight
A smart investor would closely monitor Cybin's progress on the planned Phase 2 GAD study in Q1 2024, as successful advancement could significantly de-risk the investment and increase its long-term potential.
Key Numbers
- 40 — granted patents (part of Cybin's intellectual property portfolio)
- 170 — pending patent applications (part of Cybin's intellectual property portfolio)
- 25 — granted patents (directly related to the deuterated DMT program)
Key Players & Entities
- Cybin Inc. (company) — the registrant reporting positive Phase 1 data
- Doug Drysdale (person) — Chief Executive Officer of Cybin Inc.
- CYB004 (company) — proprietary deuterated DMT molecule showing robust and rapid-onset psychedelic effects
- SPL028 (company) — proprietary deuterated DMT molecule producing robust, short-duration psychedelic effects
- Generalized Anxiety Disorder (GAD) (company) — the condition targeted for a planned Phase 2 study
Forward-Looking Statements
- Cybin Inc. will successfully initiate a Phase 2 study for its deuterated DMT program in Generalized Anxiety Disorder (GAD). (Cybin Inc.) — high confidence, target: Q1 2024
- The positive Phase 1 data will lead to increased investor interest and potentially a short-term rise in Cybin Inc.'s stock price. (Cybin Inc.) — medium confidence, target: Q1 2024
FAQ
What specific type of molecules did Cybin Inc. announce positive topline data for?
Cybin Inc. announced positive topline data for its proprietary deuterated DMT molecules, specifically CYB004 and SPL028, as stated in the news release dated January 8, 2024.
What were the key findings for CYB004 in its Phase 1 study?
Intravenous (IV) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting its potential as a short-acting, scalable treatment, according to the filing.
What were the key findings for SPL028 in its Phase 1 study?
Intramuscular (IM) dosing of SPL028 produced robust, short-duration psychedelic effects in the majority of participants, as detailed in the January 8, 2024 news release.
What is the next step for Cybin's deuterated DMT program, and when is it expected?
The combined Phase 1 results support progression to a Phase 2 study in Generalized Anxiety Disorder (GAD), which is expected to commence in Q1 2024.
How extensive is Cybin's patent portfolio related to its deuterated DMT program?
Cybin's patent portfolio includes 40 granted patents and over 170 pending applications, with 25 granted patents directly related to the deuterated DMT program, as highlighted in the filing.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 10.6 · Accepted 2024-01-08 14:40:07
Filing Documents
- cybininc-form6xk01x08x2024.htm (6-K) — 11KB
- a1-8x2024cyb004spl028phase.htm (EX-99.1) — 29KB
- image_0.jpg (GRAPHIC) — 14KB
- 0001628280-24-000817.txt ( ) — 60KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2024. Commission File Number 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CYBIN INC. (Registrant) Date January 8, 2024 By s Doug Drysdale Name Doug Drysdale Title Chief Executive Officer EXHIBIT INDEX 99.1 News Release dated January 8, 2024